Literature DB >> 17941262

Prenatal diagnoses and outcomes of congenital diaphragmatic hernia.

M Ryan Laye1, Jonathan F Rehberg, Mary Ann Kosek, Laura K Bufkin, James A Bofill.   

Abstract

OBJECTIVE: To describe the prenatal diagnoses and clinical outcomes of congenital diaphragmatic hernia (CDH).
METHODS: A retrospective case series was developed by reviewing 16,983 ultrasounds performed between March 2003 and January 2006 for the prenatal diagnosis of CDH. Medical records of each mother/infant pair were reviewed for demographic information, ultrasound findings, obstetric management, and outcomes.
RESULTS: Nineteen fetuses were diagnosed with CDH. Only one was lost to follow-up. Median gestational age at diagnosis was 28.4W (range 17.6-36.6). Fifteen cases (79%) were left sided, 3 (16%) were right-sided, and 1 (5%) was bilateral. Seven fetuses (39%) had additional abnormalities, the most common being a single umbilical artery. Ten patients (52.6%) underwent amniocentesis for karyotype; none were aneuploid. Three patients developed hydramnios. All 18 infants were liveborn. Seven infants (39%) died shortly after birth, 6 (33%) underwent surgery with subsequent discharge, and 5 (28%) were transferred to another center. Three of these died after transfer.
CONCLUSION: Prenatal diagnosis of CDH portends a poor prognosis. Thirty-nine percent of infants with this diagnosis (7/18) did not survive to undergo surgery or transfer to another facility and overall mortality was 56% (10/18). Targeted ultrasonography, extensive counseling of parents, and delivery at a tertiary care center is recommended.

Entities:  

Mesh:

Year:  2007        PMID: 17941262

Source DB:  PubMed          Journal:  J Miss State Med Assoc        ISSN: 0026-6396


  1 in total

1.  Prenatal Diagnosis of Congenital Diaphragmatic Hernia: Does Laterality Predict Perinatal Outcomes?

Authors:  Jeffrey D Sperling; Teresa N Sparks; Victoria K Berger; Jody A Farrell; Kristen Gosnell; Roberta L Keller; Mary E Norton; Juan M Gonzalez
Journal:  Am J Perinatol       Date:  2018-01-05       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.